FDA approves use of Evusheld

FDA approves use of Evusheld

The Food and Drug Administration has approved the use of Evusheld, a combination of long-acting antibodies, for prevention of Covid-19, FDA director Paisal Dankhum said on Wednesday.

Evusheld combines monoclonal antibodies for the prevention, not treatment, of Covid-19. It is not intended to be a substitute for coronavirus vaccines.

It was developed by AstraZeneca and approved by the FDA for emergency use on June 27. It has also been authorised for emergency use by the US Food and Drug Administration and the European Union.

Evusheld is a combination of two active substances, tixagevimab co-packaged with cilgavimab, and works on the principle of "passive immunisation".

It is administered as two injections, with protection lasting for at least six months.

It can be used in adults and children from 12 years of age up weighing at least 40 kilogrammes.

Dr Paisal said people who need to use this medicine should provide doctors with information such as their history of allergies, treatment for coronary artery disease, pregnancy and vaccination history.

Do you like the content of this article?
COMMENT (6)

Dust levels unsafe in 53 provinces, including Bangkok

PM2.5 dust levels above the safe limit of 50 microgrammes per cubic metre were reported in 53 provinces across the country, including Bangkok and its suburbs, on Wednesday morning.

12:43

Economy may grow 4% on tourism - minister

Thailand's economy could grow as much as 4% this year, which would be the fastest rate in five years, bolstered by a rebound in the tourism sector and increased domestic consumption, Deputy Prime Minister and Energy Minister Supattanapong Punmeechaow said on Wednesday.

12:25

Vape gouge

A Pattaya police sergeant transferred pending investigation for allegedly demanding 60,000 baht from a foreign tourist for possession of an e-cigarette.

12:16